Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 11/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381981 | 0.93 | HTR7 (0.49) | HTR7HTR1AUTS2RSSTR5KCNH2 | |
| SCHEMBL7348639 | 0.92 | HTR7 (0.44) | HTR7HTR1AUTS2RSSTR5KCNH2 | |
| SCHEMBL7347807 | 0.89 | HTR7 (0.53) | HTR7HTR1ASSTR5 | |
| SCHEMBL7351795 | 0.89 | HTR7 (0.44) | HTR7HTR1AUTS2R | |
| SCHEMBL6823392 | 0.87 | HTR7 (0.49) | HTR7HTR1AUTS2RACHE | |
| SCHEMBL6824342 | 0.86 | HTR7 (0.43) | HTR7HTR1AUTS2RSSTR5KCNH2 | |
| SCHEMBL6820561 | 0.86 | UTS2R (0.45) | HTR7HTR1AUTS2RSSTR5KCNH2 | |
| SCHEMBL6462162 | 0.86 | MCHR1 (0.43) | HTR7HTR1AUTS2RSSTR5KCNH2 | |
| SCHEMBL6462165 | 0.86 | MCHR1 (0.43) | HTR7HTR1AUTS2RSSTR5KCNH2 | |
| SCHEMBL6824741 | 0.85 | HTR7 (0.47) | HTR7HTR1AUTS2RSSTR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6307051-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTAGONISTS AND HAVE ANTITUMOR AND ANTIMETASTATIC ACTIVITY. | ROCHE DIAGNOSTICS GMBH (DE) | 2001-10-23 | — | — | US | disclosed |
| EP-1026165-A1 | O-substituted Hydroxycoumaranone derivatives as antitumor and antimetastatic agents | Roche Diagnostics GmbH (DE) | 2000-08-09 | — | — | EP | disclosed |